Achievements "OCATA Therapeutics" (MA, USA; and its collaborators have discovered a new method to generate a potent and replenishable population of MSCs from pluripotent stem cells [1] . This new and proprietary population of pluripotent stem cell-derived MSCs display potent immunomod - ulatory and therapeutic properties and has a greater than 30,000-fold proliferative capacity, relative to ordi - nary bone-marrow-derived MSCs, the most commonly used source for MSCs in clinical trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.